Treatment of Osteoporosis
Customize your policy alerts
Sign up for all Mass General Brigham Health Plan policy alerts
Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization for medically administered Evenity (romosozumab-aqqg) under the MassHealth UPPL medical benefit. It applies to treatment of osteoporosis in postmenopausal women and, off-label, in biologic males or members assigned male sex at birth who meet specified clinical and prior-treatment criteria.
The policy removed prevention of osteoporosis as an indication for Evenity.
The policy separated treatment of osteoporosis in biologic males or members assigned male sex at birth as an off-label indication.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.